Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascletis Approved to Start US Trials of an Oral PD-L1 for Solid Tumors

publication date: Feb 8, 2022

Ascletis, a Hangzhou pharma, announced the US FDA has approved the company's IND for its self-developed oral PD-L1 small molecule inhibitor. ASC61 will be tested as a therapy for advanced solid tumors. Ascletis said that ASC61, an oral drug, will be easier to administer than injectable PD-1/PD-L1 antibodies. The approval was Ascletis' second US IND approval in 2022 following envafolimab, a possible cure for chronic hepatitis B. Ascletis started with a focus on anti-viral drugs with an emphasis on hepatitis C and has expanded into oncology. More details....

Stock Symbol: (HK: 1672)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.